Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.39 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 3/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6051167 | 0.92 | FFAR1 (0.39) | ADAMTS4MMP13LMNAHTTABCB1 | |
| SCHEMBL4340869 | 0.91 | LMNA (0.40) | MAOBADAMTS4MMP13LMNAHTT | |
| SCHEMBL4347227 | 0.91 | ADAMTS4 (0.46) | MAOBADAMTS4MMP13LMNAHTT | |
| SCHEMBL4344234 | 0.89 | LMNA (0.39) | ADAMTS4MMP13LMNAHTTMMP1 | |
| SCHEMBL4339848 | 0.89 | HTT (0.41) | LMNAHTTADAM17ABCB1TAS2R14 | |
| SCHEMBL4353025 | 0.88 | ADAMTS4 (0.40) | MAOBADAMTS4MMP13LMNAHTT | |
| SCHEMBL13630997 | 0.86 | ABCB1 (0.50) | MAOBADAMTS4MMP13LMNAHTT | |
| SCHEMBL4352479 | 0.86 | MMP13 (0.40) | ADAMTS4MMP13LMNAHTTMMP1 | |
| SCHEMBL4347715 | 0.86 | LMNA (0.40) | MAOBADAMTS4MMP13LMNAHTT | |
| SCHEMBL4347719 | 0.86 | ABCB1 (0.39) | ADAMTS4MMP13LMNAHTTABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| EP-1194404-B1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2006-05-03 | — | — | EP | disclosed |
| US-6878728-B1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040122000-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED. | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122000-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | MAOB 4144/4885ADAMTS4 508/4885MMP13 900/4885 |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | MAOB 4144/4885ADAMTS4 508/4885MMP13 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.